Jincheng Medicine: Subsidiary obtains approval for the listing of Mirtazapine API.

Jincheng Pharmaceuticals announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the "Approval Notice for Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, approving the listing of mirabegron raw materials. Mirabegron is a selective -3 adrenergic receptor agonist, mainly used for the treatment of overactive bladder syndrome. According to IMS data, the global consumption of mirabegron raw materials is expected to be 57.91 tons, 63.05 tons, and 69.79 tons from 2022 to 2024 respectively. This approval will enrich the company's raw material product line and enhance market competitiveness.